

I-Isvezja-Stokholma: Tagħmir tal-laboratorju, ottiku u ta' preċiżjoni (minbarra nuċċalijiet)

OJ S 51/2018 14/03/2018

Avviż għal trasparenza ex ante volontarja

Servizzi

Il-baži ġuridika:

Direttiva 2014/24/UE

Taqsim I: Awtorità/entità kontraenti

I.1. Isem u indirizzi

Isem uffiċjali: Kungliga Tekniska högskolan

Numru ta' registrazzjoni nazzjonali: 202100-3054

Indirizz postali: Roslagstullsbacken 21

Belt: Stockholm

Kodiċi NUTS: SE11 Stockholm

Kodiċi postali: 10691

Pajjiż: L-Iżvezja

Persuna ta' kuntatt: Kicki Holmberg

Posta elettronika: hoki@kth.se

Indirizz(i) tal-Internet:

Indirizz ewlieni: <http://www.kth.se>

I.4. Tip ta' awtorità kontraenti

Aġenzija/uffiċċju nazzjonali jew federali

I.5. Attività ewlenija

Edukazzjoni

Taqsim II: L-għan

II.1. L-għan tal-ksib

II.1.1. Titlu

Large scale protein production

Numru ta' referenza: C-2018-0376

II.1.2. Kodiċi ewlieni CPV

38000000 Tagħmir tal-laboratorju, ottiku u ta' preċiżjoni (minbarra nuċċalijiet)

II.1.3. It-tip ta' kuntratt

Servizzi

II.1.4. Deskrizzjoni qasira

The Secretome project within the Wallenberg Center for protein research at the royal institute of technology needs larger amounts of specific proteins that previously have been produced in our high-throughput protein production workflow. In order to get reproducible results we need to use the same expression system (QMCF Technology) throughout the study, from small-scale to large-scale.

II.1.6.

Informazzjoni dwar il-lottijiet

Dan il-kuntratt huwa maqsum f'lottijiet: le

II.1.7. Valur totali tal-ksib

Valur mingħajr VAT: 30 000,00 EUR

II.2. Deskrizzjoni

II.2.2. Kodiċi(jiet) addizzjonali tal-VKK

73100000 Servizzi ta' riċerka u żvilupp sperimentali, 73110000 Servizzi ta' riċerka, 73300000 Disinn u eżekuzzjoni tar-riċerka u l-iżvilupp

II.2.3. Il-post tat-twettiq

Kodiċi NUTS: SE110 Stockholms län

Kodiċi NUTS: SE110 Stockholms län

II.2.4. Deskrizzjoni tal-akkwist

The Secretome project within the Wallenberg Center for protein research at the royal institute of technology has set up a high-throughput protein production pipeline based on the QMCF Technology. This enables us to produce small amounts of many proteins. For further development we need larger amounts of specific proteins that previously have been produced in the high-throughput protein production workflow. In order to get reproducible and compatible results, we need to use the same expression system throughout the study, from small-scale to large-scale. Icosagen Cell Factory OÜ is the only service provider using QMCF technology.

II.2.5. Kriterji tal-għoti

II.2.11. Informazzjoni dwar l-għażliet

Għażliet: le

II.2.13. Informazzjoni dwar Fondi tal-Unjoni Ewropea

L-akkwist huwa marbut ma' proġett u/jew programm iffinanzjat mill-fondi tal-Unjoni Ewropea: le

II.2.14. Informazzjoni addizzjonali

Taqsim IV: Proċedura

IV.1. Deskrizzjoni

IV.1.1. Tip ta' proċedura

Għoti ta' kuntratt mingħajr pubblikazzjoni minn qabel ta' sejha għall-kompetizzjoni f'Il-Gurnal Uffiċjali tal-Unjoni Ewropea fil-każijiet elenkati hawn taħt

- L-akkwist ma jaqax fl-ambitu tal-applikazzjoni tad-direttiva

Spjegazzjoni:

The Secretome project within the Wallenberg Center for protein research at the royal institute of technology has since the start of the project (2013) been using a technology called the QMCF Technology (Patent number: EP1851319). The QMCF Technology, developed by the Estonian company Icosagen Cell Factory OÜ, is an expression system that uses specific mammalian cells (QMCF cell lines) and vectors (QMCF plasmids) for production of recombinant proteins. By using this technology we are able to produce a large number of recombinant proteins in Chinese Hamster Ovary (CHO) cells yearly. Other expression systems have been tested, but the QMFC Technology was chosen to be the best alternative. Today we

have generated over 3 000 expression vectors that all are designed to work exclusively in Icosagen QMCF cells.

As a part of further development of the project we need larger amounts of specific proteins that have been produced in the high-throughput protein production (HTPP) workflow. We do not have the possibility to run large-scale production and the needed quality controls in this scale, so we need to buy this service. In order to get reproducible and compatible results, we need to use the same expression system throughout the study, from small-scale to large-scale. Small-scale production data as well as expression vectors are designed to work exclusively in Icosagen's QMCF cells therefore we need to use the QMCF Technology even for the large-scale production. Since Icosagen Cell Factory OÜ is the only service provider using QMCF technology the service will be purchased from them.

IV.1.3. Informazzjoni dwar ftehim qafas

IV.1.8. Informazzjoni dwar il-Ftehim dwar l-Akkwisti Pubbliċi (GPA)

L-akkwist huwa kopert mill-GPA: iva

IV.2. Informazzjoni amministrattiva

Taqsim V: Għoti ta' kuntratt/konċessjoni

V.2. Għoti ta' kuntratt/konċessjoni

V.2.1. Data tad-deċiżjoni dwar l-għoti tal-kuntratt

08/03/2018

V.2.2. Informazzjoni dwar sejniet għall-offerti

Il-kuntratt ingħata lil grupp ta' operaturi ekonomiċi: le

V.2.3. L-isem u l-indirizz tal-kuntrattur/konċessjonarju

Isem uffiċjali: Icosagen Cell Factory OÜ

Belt: Tartu maakond

Kodiċi NUTS: EE0 Eesti

Pajjiż: L-Estonja

Il-kuntrattur/konċessjonarju se jkun SME: iva

V.2.4. Informazzjoni dwar il-valur tal-kuntratt/lott/konċessjoni

Valur totali tal-kuntratt/lott/konċessjoni: 30 000,00 EUR

V.2.5. Informazzjoni dwar is-sottokuntrattar

Taqsim VI: Informazzjoni kumplimentari

VI.3. Informazzjoni addizzjonali

Visma notice: <https://opic.com/id/afkwrqpveo>

VI.4. Proċeduri ta' analiżi mill-ġdid

VI.4.1. Korp responsabbli għall-proċeduri ta' analiżi mill-ġdid

Isem uffiċjali: Förvaltningsrätten i Stockholm

Belt: Stockholm

Pajjiż: L-Iżvezja

VI.5.

